Dr. Riedell on the Effects of Time to Relapse on Outcomes in MCL

Peter Riedell, MD, assistant professor of medicine, University of Chicago Medicine, discusses the effects of time to relapse on outcomes in mantle cell lymphoma (MCL).

Findings from an analysis examining the effect of time to relapse on overall survival (OS) in patients with MCL following frontline treatment with high-dose therapy and autologous hematopoietic cell transplantation (AHCT) demonstrated that relapse in MCL following AHCT defines a high-risk group with inferior post-relapse OS.

Other data in other non-Hodgkin lymphoma subtypes like follicular lymphoma have also shed light on how the timing of relapse affects long-term outcomes, Riedell explains.

Ultimately, these data suggest that treatment strategies should be adapted based on timing of relapse following AHCT and that these higher-risk patients should be considered for clinical trials or novel approaches, such as CAR T-cell therapy, Riedell concludes.